

0731-06 / AF IN  
JUL 27 2006 Box 562

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/698,228-Conf. #7445
		Filing Date	October 30, 2003
		First Named Inventor	Hirofumi Arakawa
		Art Unit	1656
		Examiner Name	S. Swope
Total Number of Pages in This Submission		Attorney Docket Number	
		56801DIV(46342)	

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input checked="" type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	-Return Receipt Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	-Amendment Transmittal (1 page)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s)	-Sequence Listing Diskette
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	-Sequence Listing Paper Copy (9 pages)
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		-Statement to Support Filing and Submission (1 page)
		-Drawings (8 sheets)
Remarks		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	EDWARDS ANGELL PALMER & DODGE LLP		
Signature			
Printed name	Mark D. Russett		
Date	July 27, 2006	Reg. No.	41,281

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EV 756262001 US, on the date shown below in an envelope addressed to:  
MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 27, 2006

Signature: (Mark D. Russett)



## AMENDMENT TRANSMITTAL LETTER

Docket No.  
56801DIV(46342)

Application No.  
10/698,228-Conf. #7445

Filing Date  
October 30, 2003

Examiner  
S. Swope

Art Unit  
1656

Applicant(s): Hirofumi Arakawa et al.

Invention: PROTEIN HAVING RIBONUCLEOTIDE REDUCTASE ACTIVITY AND DNA THEREOF  
(as amended)

### TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
<b>Total Claims</b>	31	- 31 =		X	
<b>Independent Claims</b>	4	- 4 =		X	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:</b>					0.00

Large Entity

Small Entity

No additional fee is required for this amendment.

Please charge Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_.  
A duplicate copy of this sheet is enclosed.


A check in the amount of \$ \_\_\_\_\_ to cover the filing fee is enclosed.

Payment by credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 04-1105  
as described below. A duplicate copy of this sheet is enclosed.

Credit any overpayment.

Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.

  
Mark D. Russett


Attorney/Agent Reg. No.: 41,281


EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 439-4444

Dated: July 27, 2006

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EV 756262001 US, on the date shown below in an envelope addressed to:  
MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 27, 2006

Signature:  (Mark D. Russett)

O P E  
JUL 27 2006  
PATENT & TRADEMARK OFFICE  
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EV 756262001 US, on the date shown below in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
Dated: July 27, 2006      Signature:   
(Mark D. Russett)

Docket No.: 56801DIV(46342)  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Y. Nakamura et al.

Application No.: 10/698,228

Confirmation No.: 7445

Filed: October 30, 2003

Art Unit: 1656

For: PROTEIN HAVING RIBONUCLEOTIDE  
REDUCTASE ACTIVITY AND DNA  
THEREOF (as amended)

Examiner: Swope, Sheridan

MS AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

### AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION

Dear Sir:

#### INTRODUCTORY COMMENTS

Applicants are in receipt of the Office Action dated April 27, 2006 ("the Office Action"). Please amend the above-identified U.S. patent application as indicated below and consider the remarks that follow:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 7 of this paper.

**Remarks/Arguments** begin on page 8 of this paper.